Larissa Wintle
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Larissa Wintle has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
- Rikki A. M. Brown
Laboratory for Cancer Medicine, Harry Perkins Institute of Medical Research, The University of Western Australia Centre for Medical Research, Perth, WA 6000, Australia
4 shared publications - Felicity C. Kalinowski
Laboratory for Cancer Medicine, Harry Perkins Institute of Medical Research, The University of Western Australia Centre for Medical Research, Perth, WA 6000, Australia
3 shared publications Kirsty L. Richardson
Laboratory for Cancer Medicine, Harry Perkins Institute of Medical Research and the University of Western Australia Centre for Medical Research,Nedlands,Australia
3 shared publicationsLisa M. Stuart
Laboratory for Cancer Medicine, Harry Perkins Institute of Medical Research and the University of Western Australia Centre for Medical Research,Nedlands,Australia
3 shared publications- Peter J. Leedman
Laboratory for Cancer Medicine, Harry Perkins Institute of Medical Research, QEII Medical Centre, Perth, WA 6009, Australia
3 shared publications Ben Genevieve
Keogh Institute for Medical Research, Sir Charles Gairdner Hospital, Nedlands, Australia
2 shared publications
Latest Publications
- Open Access
Systematic Review and Meta-Analysis of microRNA-7-5p Expression and Biological Significance in Head and Neck Squamous Cell Carcinoma
Background: Head and neck squamous cell carcinoma (HNSCC) is a prevalent malignancy with poor clinical outcomes. microRNA-7-5p (miR-7-5p) has been described as both a tumour suppressor and an oncomiR depending on the tissue context, but its role in HNSCC remains unclear. This study aimed to clarify the clinical significance and biological function of miR-7-5p in HNSCC by integrating data from multiple sources. Methods: A systematic review of the literature was conducted to identify studies analysing miRNA expression in human head and neck tissues. A meta-analysis of individual patient data from Gene Expression Omnibus (GEO), ArrayExpress, and The Cancer Genome Atlas (TCGA) was performed to assess miR-7-5p expression in tumours and normal tissues, and its associations with clinical parameters and prognostic outcomes. Bioinformatics analyses were used to predict miR-7-5p target genes, classify hub genes, and perform gene ontology enrichment analysis. MicroRNA in situ hybridisation (miRNA ISH) and real-time quantitative PCR (RT-qPCR) were conducted on tissue samples, HNSCC cell lines, and an in vitro model of oral oncogenesis to validate miR-7-5p expression patterns. Results: miR-7-5p was significantly upregulated in tumours compared to normal tissues and associated with larger tumour size, HPV-negative status, poor disease-specific survival, and shorter progression-free intervals. Bioinformatics analysis highlighted miR-7-5p target genes enriched in pathways related to cell growth, survival, and tumourigenesis. Despite evidence supporting the anti-cancer role of exogenous miR-7-5p in preclinical models, the observed endogenous upregulation in tumours suggests that miR-7-5p expression may represent a compensatory or stress-responsive mechanism during tumourigenesis, rather than acting as a primary oncogenic driver. Conclusions: This study provides new insights into the complex role of miR-7-5p in HNSCC, supporting its potential as both a biomarker and a therapeutic target. Understanding the context-specific functions of miR-7-5p is essential for its development as an RNA-based therapeutic in HNSCC.
Open AccessSystematic Review and Meta-Analysis of microRNA-7-5p Expression and Biological Significance in Head and Neck Squamous Cell Carcinoma
Background: Head and neck squamous cell carcinoma (HNSCC) is a prevalent malignancy with poor clinical outcomes. microRNA-7-5p (miR-7-5p) has been described as both a tumour suppressor and an oncomiR depending on the tissue context, but its role in HNSCC remains unclear. This study aimed to clarify the clinical significance and biological function of miR-7-5p in HNSCC by integrating data from multiple sources. Methods: A systematic review of the literature was conducted to identify studies analysing miRNA expression in human head and neck tissues. A meta-analysis of individual patient data from Gene Expression Omnibus (GEO), ArrayExpress, and The Cancer Genome Atlas (TCGA) was performed to assess miR-7-5p expression in tumours and normal tissues, and its associations with clinical parameters and prognostic outcomes. Bioinformatics analyses were used to predict miR-7-5p target genes, classify hub genes, and perform gene ontology enrichment analysis. MicroRNA in situ hybridisation (miRNA ISH) and real-time quantitative PCR (RT-qPCR) were conducted on tissue samples, HNSCC cell lines, and an in vitro model of oral oncogenesis to validate miR-7-5p expression patterns. Results: miR-7-5p was significantly upregulated in tumours compared to normal tissues and associated with larger tumour size, HPV-negative status, poor disease-specific survival, and shorter progression-free intervals. Bioinformatics analysis highlighted miR-7-5p target genes enriched in pathways related to cell growth, survival, and tumourigenesis. Despite evidence supporting the anti-cancer role of exogenous miR-7-5p in preclinical models, the observed endogenous upregulation in tumours suggests that miR-7-5p expression may represent a compensatory or stress-responsive mechanism during tumourigenesis, rather than acting as a primary oncogenic driver. Conclusions: This study provides new insights into the complex role of miR-7-5p in HNSCC, supporting its potential as both a biomarker and a therapeutic target. Understanding the context-specific functions of miR-7-5p is essential for its development as an RNA-based therapeutic in HNSCC.
- 29 November 2017
- Published by Wolters Kluwer Health in Hepatology
- Vol. 67 (1) , 216-231
A microRNA‐7/growth arrest specific 6/TYRO3 axis regulates the growth and invasiveness of sorafenib‐resistant cells in human hepatocellular carcinoma
Sorafenib remains the only approved drug for treating patients with advanced hepatocellular carcinoma (HCC). However, the therapeutic effect of sorafenib is transient, and patients invariably develop sorafenib resistance (SR). Recently, TYRO3, a member of the TYRO3‐AXL‐MER family of receptor tyrosine kinases, was identified as being aberrantly expressed in a significant proportion of HCC; however, its role in SR is unknown. In this study, we generated two functionally distinct sorafenib‐resistant human Huh‐7 HCC cell lines in order to identify new mechanisms to abrogate acquired SR as well as new potential therapeutic targets in HCC. Initially, we investigated the effects of a microRNA (miR), miR‐7‐5p (miR‐7), in both in vitro and in vivo preclinical models of human HCC and identified miR‐7 as a potent tumor suppressor of human HCC. We identified TYRO3 as a new functional target of miR‐7, which regulates proliferation, migration, and invasion of Huh‐7 cells through the phosphoinositide 3‐kinase/protein kinase B pathway and is markedly elevated with acquisition of SR. Furthermore, miR‐7 effectively silenced TYRO3 expression in both sorafenib‐sensitive and sorafenib‐resistant Huh‐7 cells, inhibiting TYRO3/growth arrest specific 6‐mediated cancer cell migration and invasion. Conclusion: We identified a mechanism for acquiring SR in HCC that is through the aberrant expression of the TYRO3/phosphoinositide 3‐kinase/protein kinase B signal transduction pathway, and that can be overcome by miR‐7 overexpression. Taken together, these data suggest a potential role for miR‐7 as an RNA‐based therapeutic to treat refractory and drug‐resistant HCC. (Hepatology 2018;67:216‐231)
- 29 November 2017
- Published by Wolters Kluwer Health in Hepatology
- Vol. 67 (1) , 216-231
A microRNA‐7/growth arrest specific 6/TYRO3 axis regulates the growth and invasiveness of sorafenib‐resistant cells in human hepatocellular carcinoma
Sorafenib remains the only approved drug for treating patients with advanced hepatocellular carcinoma (HCC). However, the therapeutic effect of sorafenib is transient, and patients invariably develop sorafenib resistance (SR). Recently, TYRO3, a member of the TYRO3‐AXL‐MER family of receptor tyrosine kinases, was identified as being aberrantly expressed in a significant proportion of HCC; however, its role in SR is unknown. In this study, we generated two functionally distinct sorafenib‐resistant human Huh‐7 HCC cell lines in order to identify new mechanisms to abrogate acquired SR as well as new potential therapeutic targets in HCC. Initially, we investigated the effects of a microRNA (miR), miR‐7‐5p (miR‐7), in both in vitro and in vivo preclinical models of human HCC and identified miR‐7 as a potent tumor suppressor of human HCC. We identified TYRO3 as a new functional target of miR‐7, which regulates proliferation, migration, and invasion of Huh‐7 cells through the phosphoinositide 3‐kinase/protein kinase B pathway and is markedly elevated with acquisition of SR. Furthermore, miR‐7 effectively silenced TYRO3 expression in both sorafenib‐sensitive and sorafenib‐resistant Huh‐7 cells, inhibiting TYRO3/growth arrest specific 6‐mediated cancer cell migration and invasion. Conclusion: We identified a mechanism for acquiring SR in HCC that is through the aberrant expression of the TYRO3/phosphoinositide 3‐kinase/protein kinase B signal transduction pathway, and that can be overcome by miR‐7 overexpression. Taken together, these data suggest a potential role for miR‐7 as an RNA‐based therapeutic to treat refractory and drug‐resistant HCC. (Hepatology 2018;67:216‐231)
- 31 October 2017
- Published by Springer Nature
- Vol. 1699, 155-178
Evaluation of MicroRNA Delivery In Vivo
MicroRNAs (miRNAs) are a family of short noncoding RNA molecules that fine-tune expression of mRNAs. Often their altered expression is associated with a number of diseases, including cancer. Given that miRNAs target multiple genes and "difficult to drug" oncogenes, they present attractive candidates to manipulate as an anti-cancer strategy. MicroRNA-7 (miR-7) is a tumor suppressor miRNA that has been shown to target oncogenes overexpressed in cancers, such as the epidermal growth factor receptor (EGFR) and the nuclear factor-κ B subunit, RelA. Here, we describe methods for evaluating systemic delivery of miR-7 using a lipid nanoparticle formulation in an animal model. The microRNA is delivered three times, over 1 week and tissues collected 24 h after the last injection. RNA and protein are extracted from snap frozen tissues and processed to detect miRNA distribution and subsequent assessment of downstream targets and signaling mediators, respectively. Importantly, variability in efficiency of miRNA delivery will be observed between organs of the same animal and also between animals. Additionally, delivering the microRNA to organs other than the liver, particularly the brain, remains challenging. Furthermore, large variation in miRNA targets is seen both within tissues and across tissues depending on the lysis buffer used for protein extraction. Therefore, analyzing protein expression is dependent upon the method used for isolation and requires optimization for each individual application. Together, these methods will provide a foundation for those planning on assessing the efficacy of delivery of a miRNA in vivo.
- 31 October 2017
- Published by Springer Nature
- Vol. 1699, 155-178
Evaluation of MicroRNA Delivery In Vivo
MicroRNAs (miRNAs) are a family of short noncoding RNA molecules that fine-tune expression of mRNAs. Often their altered expression is associated with a number of diseases, including cancer. Given that miRNAs target multiple genes and "difficult to drug" oncogenes, they present attractive candidates to manipulate as an anti-cancer strategy. MicroRNA-7 (miR-7) is a tumor suppressor miRNA that has been shown to target oncogenes overexpressed in cancers, such as the epidermal growth factor receptor (EGFR) and the nuclear factor-κ B subunit, RelA. Here, we describe methods for evaluating systemic delivery of miR-7 using a lipid nanoparticle formulation in an animal model. The microRNA is delivered three times, over 1 week and tissues collected 24 h after the last injection. RNA and protein are extracted from snap frozen tissues and processed to detect miRNA distribution and subsequent assessment of downstream targets and signaling mediators, respectively. Importantly, variability in efficiency of miRNA delivery will be observed between organs of the same animal and also between animals. Additionally, delivering the microRNA to organs other than the liver, particularly the brain, remains challenging. Furthermore, large variation in miRNA targets is seen both within tissues and across tissues depending on the lysis buffer used for protein extraction. Therefore, analyzing protein expression is dependent upon the method used for isolation and requires optimization for each individual application. Together, these methods will provide a foundation for those planning on assessing the efficacy of delivery of a miRNA in vivo.
- Open Access
- 17 May 2016
- Published by Impact Journals, LLC in Oncotarget
- Vol. 7 (22) , 31663-31680
microRNA-7-5p inhibits melanoma cell proliferation and metastasis by suppressing RelA/NF-κB
MicroRNA-7-5p (miR-7-5p) is a tumor suppressor in multiple cancer types and inhibits growth and invasion by suppressing expression and activity of the epidermal growth factor receptor (EGFR) signaling pathway. While melanoma is not typically EGFR-driven, expression of miR-7-5p is reduced in metastatic tumors compared to primary melanoma. Here, we investigated the biological and clinical significance of miR-7-5p in melanoma. We found that augmenting miR-7-5p expression in vitro markedly reduced tumor cell viability, colony formation and induced cell cycle arrest. Furthermore, ectopic expression of miR-7-5p reduced migration and invasion of melanoma cells in vitro and reduced metastasis in vivo. We used cDNA microarray analysis to identify a subset of putative miR-7-5p target genes associated with melanoma and metastasis. Of these, we confirmed nuclear factor kappa B (NF-κB) subunit RelA, as a novel direct target of miR-7-5p in melanoma cells, such that miR-7-5p suppresses NF-κB activity to decrease expression of canonical NF-κB target genes, including IL-1β, IL-6 and IL-8. Importantly, the effects of miR-7-5p on melanoma cell growth, cell cycle, migration and invasion were recapitulated by RelA knockdown. Finally, analysis of gene array datasets from multiple melanoma patient cohorts revealed an association between elevated RelA expression and poor survival, further emphasizing the clinical significance of RelA and its downstream signaling effectors. Taken together, our data show that miR-7-5p is a potent inhibitor of melanoma growth and metastasis, in part through its inactivation of RelA/NF-κB signaling. Furthermore, miR-7-5p replacement therapy could have a role in the treatment of this disease.
- 17 May 2016
- Published by Impact Journals, LLC in Oncotarget
- Vol. 7 (22) , 31663-31680
Open AccessmicroRNA-7-5p inhibits melanoma cell proliferation and metastasis by suppressing RelA/NF-κB
MicroRNA-7-5p (miR-7-5p) is a tumor suppressor in multiple cancer types and inhibits growth and invasion by suppressing expression and activity of the epidermal growth factor receptor (EGFR) signaling pathway. While melanoma is not typically EGFR-driven, expression of miR-7-5p is reduced in metastatic tumors compared to primary melanoma. Here, we investigated the biological and clinical significance of miR-7-5p in melanoma. We found that augmenting miR-7-5p expression in vitro markedly reduced tumor cell viability, colony formation and induced cell cycle arrest. Furthermore, ectopic expression of miR-7-5p reduced migration and invasion of melanoma cells in vitro and reduced metastasis in vivo. We used cDNA microarray analysis to identify a subset of putative miR-7-5p target genes associated with melanoma and metastasis. Of these, we confirmed nuclear factor kappa B (NF-κB) subunit RelA, as a novel direct target of miR-7-5p in melanoma cells, such that miR-7-5p suppresses NF-κB activity to decrease expression of canonical NF-κB target genes, including IL-1β, IL-6 and IL-8. Importantly, the effects of miR-7-5p on melanoma cell growth, cell cycle, migration and invasion were recapitulated by RelA knockdown. Finally, analysis of gene array datasets from multiple melanoma patient cohorts revealed an association between elevated RelA expression and poor survival, further emphasizing the clinical significance of RelA and its downstream signaling effectors. Taken together, our data show that miR-7-5p is a potent inhibitor of melanoma growth and metastasis, in part through its inactivation of RelA/NF-κB signaling. Furthermore, miR-7-5p replacement therapy could have a role in the treatment of this disease.
- Open Access
- 15 August 2013
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (8) , e70700
Loss of the Nuclear Receptor Corepressor SLIRP Compromises Male Fertility
Nuclear receptors (NRs) and their coregulators play fundamental roles in initiating and directing gene expression influencing mammalian reproduction, development and metabolism. SRA stem Loop Interacting RNA-binding Protein (SLIRP) is a Steroid receptor RNA Activator (SRA) RNA-binding protein that is a potent repressor of NR activity. SLIRP is present in complexes associated with NR target genes in the nucleus; however, it is also abundant in mitochondria where it affects mitochondrial mRNA transcription and energy turnover. In further characterisation studies, we observed SLIRP protein in the testis where its localization pattern changes from mitochondrial in diploid cells to peri-acrosomal and the tail in mature sperm. To investigate the in vivo effects of SLIRP, we generated a SLIRP knockout (KO) mouse. This animal is viable, but sub-fertile. Specifically, when homozygous KO males are crossed with wild type (WT) females the resultant average litter size is reduced by approximately one third compared with those produced by WT males and females. Further, SLIRP KO mice produced significantly fewer progressively motile sperm than WT animals. Electron microscopy identified disruption of the mid-piece/annulus junction in homozygous KO sperm and altered mitochondrial morphology. In sum, our data implicates SLIRP in regulating male fertility, wherein its loss results in asthenozoospermia associated with compromised sperm structure and mitochondrial morphology.
- 15 August 2013
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (8) , e70700
Open AccessLoss of the Nuclear Receptor Corepressor SLIRP Compromises Male Fertility
Nuclear receptors (NRs) and their coregulators play fundamental roles in initiating and directing gene expression influencing mammalian reproduction, development and metabolism. SRA stem Loop Interacting RNA-binding Protein (SLIRP) is a Steroid receptor RNA Activator (SRA) RNA-binding protein that is a potent repressor of NR activity. SLIRP is present in complexes associated with NR target genes in the nucleus; however, it is also abundant in mitochondria where it affects mitochondrial mRNA transcription and energy turnover. In further characterisation studies, we observed SLIRP protein in the testis where its localization pattern changes from mitochondrial in diploid cells to peri-acrosomal and the tail in mature sperm. To investigate the in vivo effects of SLIRP, we generated a SLIRP knockout (KO) mouse. This animal is viable, but sub-fertile. Specifically, when homozygous KO males are crossed with wild type (WT) females the resultant average litter size is reduced by approximately one third compared with those produced by WT males and females. Further, SLIRP KO mice produced significantly fewer progressively motile sperm than WT animals. Electron microscopy identified disruption of the mid-piece/annulus junction in homozygous KO sperm and altered mitochondrial morphology. In sum, our data implicates SLIRP in regulating male fertility, wherein its loss results in asthenozoospermia associated with compromised sperm structure and mitochondrial morphology.
- 1 June 2011
- Published by The Endocrine Society
- p. P1-31
Loss of the Nuclear Receptor Corepressor SLIRP Compromises Male Fertility In Vivo
Nuclear receptors (NRs) and their coregulators play fundamental roles in initiating and directing gene expression influencing mammalian reproduction, development and metabolism. SRA stem Loop Interacting RNA-binding Protein (SLIRP) is a Steroid receptor RNA Activator (SRA) RNA binding protein which is a potent repressor of NR activity. SLIRP is present in NR complexes associated with NR target genes in the nucleus, however, it is also abundant in mitochondria where it may affect energy turnover. Notably, SLIRP is a potent regulator of androgen action and is expressed in the testis and more specifically within developing spermatozoa. Colocalization studies indicate SLIRP is present within the mid-piece and head of the mature sperm suggesting a functional role within this tissue. To investigate the in vivo effects of SLIRP, we have generated a SLIRP knock out (KO) mouse. This animal is viable, however when homozygous males are crossed with wild type (wt) or heterozygous females the resultant litter size is reduced by approximately one quarter (−/− x +/+, 4.8 pups/litter; −/− x −/+, 6.3) compared with those produced by wt males with comparable females (+/+ x +/+, 6.6; +/+ x −/+, 6.7). Comparison of sperm samples from males of each of the phenotypes showed that the KO mice had 60% fewer progressively motile sperm than either the wt or homozygous mice. In humans, micro-array data suggests that SLIRP mRNA levels in sperm from teratozoospermic men are frequently reduced. In sum, our data suggests that loss of SLIRP results in impaired male fertility, attributable in part, to compromised sperm motility. Nothing to Disclose: SMC, RS, LW, VR, RCF, SS, KD, BG, BS, LWS, MO, BWO, PJL
- 1 June 2011
- Published by The Endocrine Society
- p. P1-31
Loss of the Nuclear Receptor Corepressor SLIRP Compromises Male Fertility In Vivo
Nuclear receptors (NRs) and their coregulators play fundamental roles in initiating and directing gene expression influencing mammalian reproduction, development and metabolism. SRA stem Loop Interacting RNA-binding Protein (SLIRP) is a Steroid receptor RNA Activator (SRA) RNA binding protein which is a potent repressor of NR activity. SLIRP is present in NR complexes associated with NR target genes in the nucleus, however, it is also abundant in mitochondria where it may affect energy turnover. Notably, SLIRP is a potent regulator of androgen action and is expressed in the testis and more specifically within developing spermatozoa. Colocalization studies indicate SLIRP is present within the mid-piece and head of the mature sperm suggesting a functional role within this tissue. To investigate the in vivo effects of SLIRP, we have generated a SLIRP knock out (KO) mouse. This animal is viable, however when homozygous males are crossed with wild type (wt) or heterozygous females the resultant litter size is reduced by approximately one quarter (−/− x +/+, 4.8 pups/litter; −/− x −/+, 6.3) compared with those produced by wt males with comparable females (+/+ x +/+, 6.6; +/+ x −/+, 6.7). Comparison of sperm samples from males of each of the phenotypes showed that the KO mice had 60% fewer progressively motile sperm than either the wt or homozygous mice. In humans, micro-array data suggests that SLIRP mRNA levels in sperm from teratozoospermic men are frequently reduced. In sum, our data suggests that loss of SLIRP results in impaired male fertility, attributable in part, to compromised sperm motility. Nothing to Disclose: SMC, RS, LW, VR, RCF, SS, KD, BG, BS, LWS, MO, BWO, PJL